Squamous Cell Carcinoma of the Vulva: A Survival and Epidemiologic Study with Focus on Surgery and Radiotherapy.

SEER epidemiology squamous cell carcinoma survival vulva

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
16 Feb 2022
Historique:
received: 31 12 2021
revised: 07 02 2022
accepted: 14 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Vulvar squamous cell carcinoma (SCC) is the most frequent vulvar neoplasia. While the primary role of surgery is widely accepted, large population studies are needed to compare survival between diverse treatment modalities and to identify independent prognostic factors to help council patients and guide oncological treatment. The U.S. National Cancer Index, Surveillance, Epidemiology and End Results (SEER) program data between 2000 and 2018 was screened for all squamous cell carcinoma affecting the vulva. Raw data was processed with IBM SPSS. Demographic, clinical-pathological and treatment data were studied. Overall survival (OS) was calculated using the Kaplan-Meier method and subgroups were compared using the log rank test. A multivariate cox regression was conducted to identify independent prognostic factors. A total of 11,360 patients were identified with a median age of 65. Median overall survival was 101 months. Surgery as a primary treatment is the therapeutic sequence associated with the best overall survival. Multivariate cox-regression did not meet proportional hazard assumption. Age, pathological grade, stage at diagnosis, treatment sequence and the use of chemotherapy were identified as independent prognostic factor. Surgery alone is the treatment sequence offering the best overall survival. Surgery should be offered to all eligible patients.

Identifiants

pubmed: 35207308
pii: jcm11041025
doi: 10.3390/jcm11041025
pmc: PMC8880528
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Am Acad Dermatol. 2019 Dec;81(6):1387-1396
pubmed: 31349045
Am J Cancer Res. 2011 Jan 1;1(3):275-300
pubmed: 21938273
Gynecol Oncol. 2018 May;149(2):310-317
pubmed: 29555332
Gynecol Oncol. 2014 Mar;132(3):780-9
pubmed: 24296343
Eur J Cancer. 2013 Dec;49(18):3872-80
pubmed: 24011936
Gynecol Oncol. 2017 Jun;145(3):543-548
pubmed: 28356187
Int J Gynecol Cancer. 2020 Sep;30(9):1285-1291
pubmed: 32571891
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Clin Oncol. 2019 Sep;24(9):1137-1142
pubmed: 31025128
Int J Cancer. 2018 Mar 15;142(6):1158-1165
pubmed: 29090456
Histopathology. 2017 Aug;71(2):238-246
pubmed: 28257152
J Cancer Res Clin Oncol. 2016 Jun;142(6):1331-41
pubmed: 26973058
Am J Clin Oncol. 2018 Sep;41(9):845-850
pubmed: 30134287
Gynecol Oncol. 2020 Dec;159(3):663-671
pubmed: 32988623
Gynecol Oncol. 2018 Mar;148(3):474-479
pubmed: 29336837
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2061-7
pubmed: 19567503
Histopathology. 2020 Jan;76(1):128-138
pubmed: 31846523
Cancers (Basel). 2021 Aug 12;13(16):
pubmed: 34439215
J Low Genit Tract Dis. 2016 Jan;20(1):11-4
pubmed: 26704327
Gynecol Oncol. 2015 Jun;137(3):365-72
pubmed: 25868965
Gynecol Oncol. 2008 Mar;108(3):577-83
pubmed: 18155274
Gynecol Oncol. 2017 Sep;146(3):572-579
pubmed: 28662775
J Sex Med. 2012 Feb;9(2):361-71
pubmed: 22082135
Ann Transl Med. 2020 Nov;8(21):1382
pubmed: 33313127
J Natl Compr Canc Netw. 2017 Jan;15(1):92-120
pubmed: 28040721
Int J Gynecol Cancer. 2020 May;30(5):583-589
pubmed: 32184269

Auteurs

Matteo Scampa (M)

Department of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.

Daniel F Kalbermatten (DF)

Department of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.

Carlo M Oranges (CM)

Department of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, University of Geneva, 1205 Geneva, Switzerland.

Classifications MeSH